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Abstract
Background: Mathematical models can be used to predict individual growth responses to growth
hormone (GH) therapy. The aim of this study was to construct and validate high-precision models
to predict the growth response to GH treatment of short children, independent of their GH status,
birth size and gestational age. As the GH doses are included, these models can be used to
individualize treatment.
Methods: Growth data from 415 short prepubertal children were used to construct models for
predicting the growth response during the first years of GH therapy. The performance of the
models was validated with data from a separate cohort of 112 children using the same inclusion
criteria.
Results: Using only auxological data, the model had a standard error of the residuals (SDres), of
0.23 SDS. The model was improved when endocrine data (GHmax profile, IGF-I and leptin) collected
before starting GH treatment were included. Inclusion of these data resulted in a decrease of the
SDres to 0.15 SDS (corresponding to 1.1 cm in a 3-year-old child and 1.6 cm in a 7-year old).
Validation of these models with a separate cohort, showed similar SDres for both types of models.
Preterm children were not included in the Model group, but predictions for this group were within
the expected range.
Conclusion: These prediction models can with high accuracy be used to identify short children
who will benefit from GH treatment. They are clinically useful as they are constructed using data
from short children with a broad range of GH secretory status, birth size and gestational age.
Background
Prediction models are used to determine the outcome of
therapies in individual patients. Validated models for pre-
dicting individual growth responses to growth hormone
(GH) treatment have been constructed for short children
born appropriate for gestational age (AGA) who have a
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broad range of GH secretory status [1], for children with
GH deficiency (GHD) [2,3], for children born small-for-
gestational age (SGA) without severe GHD [4], and for
girls with Turner syndrome [5]. Most models have been
developed in children grouped according to birth size [4]
or GH secretory status [2,3]. However, as size at birth is a
continuum, and any statistically cut-off point chosen will
be artificial, the development of prediction models for
growth in children should be independent of birth size,
especially as a broad range of the variables used improves
the model [6]. The usefulness of prediction models is
defined by how well they perform in practice [1,6]. It is
crucial, therefore, that the model will be validated using
data from a separate group of patients. The observed
growth response to GH of a given child can be used as an
indirect marker of GH responsiveness in this same child
[7,8].
Catch-up growth during the first years of GH treatment
correlates strongly with the rest of prepubertal growth
[4,9] and with the total gain in height until adult height
[9]. Little attention has been given to the magnitude of the
catch-up growth that can be achieved when treatment is
given with a GH dose optimized according to individual
responsiveness. The goal of GH treatment during the first
years would, therefore, be to give a dose high enough to
reach the target height SD score (SDS) within a few years
without producing adverse side-effects.
The aim of this study was to develop models for individ-
ual prediction of the growth response to GH during the
first years of treatment, i.e., the catch-up phase, in slowly
growing and/or short prepubertal children who have dif-
ferent GH status, gestational age and size at birth. This
would facilitate the use of an evidence-based method to
identify those children who will benefit from GH treat-
ment and to individualize their GH treatment. The meth-
odology used was non-linear multivariate regression
analysis, and the decision of which variables to use was
based on previous publications [1,8]. Factors known to be
related closely to growth response are pretreatment
growth data, auxology at the start of GH treatment, maxi-
mum peak of the spontaneous GH secretion (GHmax)[10],
and levels of insulin-like growth factor-I (IGF-I) [11] and
leptin [12].
Methods
Study design
Data from a model group, those children beginning bio-
synthetic GH therapy during the period from 1986 to
1997, were used to construct the prediction models. Data
from a validation group of children with the same inclu-
sion criteria who started GH therapy during the period
from 1998 to 2001, after recruiting for the model group
was closed, were used to validate the prediction models.
Patients
Model group
The 415 short children were born either AGA (n = 271, 59
girls) or SGA (n = 144, 34 girls). SGA is defined as a birth
weight and or a birth length below -2 SDS, according to
Swedish reference values [13]. Isolated idiopathic GHD
was absent (n = 135) or present (n = 280), based on a cut-
off level for GHmaxof 32 mU/L (10 μg/L) from either a 24-
hour GH profile (24 h profile) or an arginine-insulin tol-
erance test (AITT).
Validation group
The validation group consisted of a separate independent
cohort of 112 children (33 girls, 79 boys) with (n = 92) or
without (n = 20) isolated idiopathic GHD, of whom 34
were born SGA.
Preterm children
A group of 36 preterm (30–36 weeks of gestation) chil-
dren (Preterm model group), of whom 22 were born SGA,
was studied to develop a simple general fine-tuning for-
mula for all models. Computations were done on the
model using the most readily available variables having
the largest number of children included. Another preterm
group of 11 children (Preterm validation group), of
whom 5 were born SGA, was used for validating preterm
predictions. Here, gestational age ranged from 27 to 36
weeks. Of the 47 preterm children, 24 were diagnosed as
having isolated idiopathic GHD.
Inclusion and exclusion criteria
All children were of Caucasian origin. They had an
uncomplicated neonatal period, without signs of severe
asphyxia (defined as an Apgar score <3 after 5 minutes)
and without sepsis in the neonatal period. Height and
weight have been measured since birth atneonatal units,
child healthcare units and schools in Sweden. The chil-
dren were well nourished and showed no clinical evi-
dence of psychosocial disorders. Criteria for exclusion
consisted of maternal history of alcohol or drug addic-
tion, chromosomal disorders, malformations, dysmor-
phic features with the exception of children with Silver-
Russell syndrome (n = 10), chondrodysplasia, diseases
other than isolated GHD and well treated hypothy-
roidism. Thyroid, kidney, and liver function tests were
normal. Children who missed GH injections for more
than 14 days per year for the first 2 years of GH treatment
were excluded. All children were prepubertal during the
study period, as defined by breast stage 1 [13] or a testic-
ular volume below 4 mL [14].
Birth weight SDS and birth length SDS used in the algo-
rithms were calculated based on the Swedish newborn
infants born 1990–94 (approximately half a million
infants) from which a "healthy"" subpopulation wasBMC Medical Informatics and Decision Making 2007, 7:40 http://www.biomedcentral.com/1472-6947/7/40
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extracted in accordance with a former reference [15]. The
improvements were that this new data set includes (a)
more of very preterm infants, which stabilizes the growth
curve at the lower end compared with the earlier refer-
ence; (b) gestational age evaluation was based on early
ultrasound; (c) mothers who delivered by cesarean sec-
tion were excluded, in order to minimize the known sur-
plus of severely growth retarded infants rescued by
intervention in the very preterm period. As a result, coeffi-
cient of variation was found to be approximately constant
over the whole period. SDS were calculated using the coef-
ficient of variation at term age (a proportionality factor
equal to SD/mean) when the calculations could be based
on the largest number of infants. The resulting algorithm
was found to be close to estimated fetal weight [16] and
was considered to describe undisturbed intrauterine
growth.
As all children were prepubertal, heights were trans-
formed into SDS for age and sex using a mathematical
childhood component of the new Swedish reference [17]
analogous to the ICP model of Karlberg et al [18], in order
to adjust for delayed puberty. Weight SDS [17] and weight
for height SDS [19] were calculated based on two pub-
lished references. Gender-adjusted target height SDS was
computed based on maternal and paternal height [20].
The paternal heights were measured at the clinic with few
exceptions. The difference in height SDS of the child com-
pared with its target height SDS is expressed as 'Diff SDS'.
Pretreatment investigations
Clinical characteristics of the patients in the Model group
and the Validation group are given in Table 1. The charac-
teristics include a broad range of GH secretion and of
birth size.
Auxological variables in the models were (a) birth weight,
(b) weight and height (SDS) at start of treatment, (c) at
least one height and weight measurement between birth
and the start of treatment, (d) maternal height SDS and
(e) paternal height SDS. The characteristics of the SGA and
preterm children are shown in Table 2. Figure 1 shows the
wide distribution in birth size of all the studied children.
The endocrine investigations were performed during the
pre-treatment year, and included a GHstimulation test,
Arginin Insulin Tolerance Test, (AITT), as described previ-
ously [21]. Also, a spontaneous 24 h GH profile with inte-
grated samples taken every 20 minutes [22] was obtained
from 188 children (40 girls, 148 boys) in the Model group
and 60 children (20 girls, 40 boys) in the Validation
group. Three other children in the Validation group had a
12 h night-time GH profile [10]. At the start of treatment,
blood samples for leptin were taken in the morning, and
for IGF-I in the afternoon, from 200 children in the Model
group and from 48 in the Validation group. The clinical
characteristics of the children from whom only auxologi-
cal information was used, were not different from the chil-
dren in whom serum IGF-I and leptin or the maximum
level of GH24 h 24 h GH profiles and maximum level of
GHAITT GHAITT were obtained (see Table 1).
Treatment
All children were treated with a daily dose of GH ranging
between 25 and 66 μg/kg based on the body weight (kg)
of the child. The exact dose was adjusted every 3 months.
Biochemical measurements
All analyses were performed at the lab of Växthuset,
accredited no 1899.
GH concentrations were measured using a time-resolved
immunofluorometic assay (Wallac, Finland), with the
WHO First International Reference Preparation (IRP) 80/
505 as the standard [23]. If another method or an earlier
standard was used, the GH concentrations were trans-
formed to comparable levels using transformation factors
derived in our laboratory [24]. Accredited no:1899.
IGF-I  was measured by an IGFBP-blocked radioimmu-
noassay (RIA) without extraction and in the presence of
an approximately 250-fold excess of IGF-II (Mediagnost,
Tübingen, Germany) [25]. IGF-I values are expressed as
SDS [26]. Accredited no:1899.
Leptin  was measured by RIA (Linco Research Inc, St
Charles, MO, USA). The detection range of the assay was
0.22 to 100 ng/ml and, the intra-assay coefficients of var-
iation were 7.0% at 2.4 ng/mL and 4.9% at 14.0 ng/ml.
The corresponding values for the interassay coefficients of
variation were 9.6% and 6.7% [27]. Accredited no:1899.
Statistics
General considerations about model fitting in prediction models
We present analyses of the standard error of the residuals
SDres, because they are independent of the numerical
value of the predicted growth response. The R2 analysis is
too sensitive for the range of the predicted extremes, (i.e.,
very high or very low responders)[6]. The model is clini-
cally valid if the SDres for the validation group of patients
is in the same range as the group of patients used to derive
the model.
Modelling
The technique used is described as non-linear data fitting
(empirical curve fitting) and empirical testing. The non-
linear approach was chosen because a non-linear relation-
ship was found between the growth response and other
variables. Overfitting was prevented, by selecting stepwise
subsets of non-linear transformed original variables thatBMC Medical Informatics and Decision Making 2007, 7:40 http://www.biomedcentral.com/1472-6947/7/40
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gave the best overall prediction result. As the growth
response curve is non-linear, a non-linear correction for
differences in measurement time (1 year ± 3 months) was
developed. The modeller had no access to the data from
the validation group and testing of the final prediction
models with the validation group, was performed by
another statistician. A computer program for calculation
of the prediction was constructed for each of the five mod-
els presented in the results section, using the algorithms
presented in Additional file 1. This program was used for
prediction of the growth response for the children in the
validation group and compared with the observed growth
response for each child.
Table 1: Characteristics of all children in the Model and Validation groups. The data presented for the Auxological model (a & b) and 
the Endocrine models (c & d).
a. Model group b. Validation group
Variables Mean SD Min Max N Mean SD Min Max N
At birth
Gestational age (weeks) 39.6 1.3 37 42 415 39.5 1.5 37 42 112
Height SDS -1.33 1.29 -5.8 2.0 415 -1.31 1.12 -5.4 1.5 112
Weight SDS -1.08 1.27 -4.5 3.2 415 -1.07 1.1 -4.4 2.3 112
Pretreatment
Δheight SDS during pretreat yr 0.01 0.18 -0.5 0.6 377 0.03 0.22 -0.66 0.68 101
GHmax of GH-profile 42.5 28.8 3.9 235.4 188 34.0 21.3 7.6 98.1 60
GHmax during AITT 28.6 24.4 1.7 229.4 387 21.9 14.5 1.4 76.1 95
At GH start
SEX (min = girls, max = boys) 93 322 415 33 79 112
Age (yrs) 8.72 2.41 3.1 13.9 415 7.88 2.19 2.8 12.2 112
Height SDS -2.87 0.6 -5.0 -1.2 415 -2.77 0.53 -4.2 -1.6 112
Weight SDS -2.56 0.94 -6.2 1.8 415 -2.38 1.09 -4.9 2.6 112
Father height SDS -1.03 1.07 -4.9 2.1 415 -0.74 1.03 -3.0 1.7 112
Mother height SDS -1.31 1 -3.8 1.6 415 -0.99 0.96 -3.1 1.5 112
Diff SDS -2.17 0.74 -5.0 -0.3 415 -2.29 0.72 -5.1 0.2 112
IGF SDS -1.11 1.55 -7.4 3.0 223 -1.23 1.5 -5.3 2.7 83
Leptin (ng/mL) 3.48 2.37 1.0 27.8 216 3.97 3.75 1.7 24.1 82
During treatment
GH dose (IU/kg/day) 0.11 0.03 0.07 0.25 415 0.11 0.02 0.08 0.2 112
Change in height SDS 1st yr 0.75 0.3 0.1 2.3 415 0.73 0.25 0.1 1.6 112
Change in height SDS two yrs 1.18 0.44 0.2 3.0 300 1.17 0.34 0.4 2.1 73
c. Model group d. Validation group
At birth
Gestational age (weeks) 39.4 1.3 37 42 140 39.6 1.4 37 42 51
Height SDS -1.77 1.35 -5.8 1.9 140 -1.33 1.12 -4.1 1.5 51
Weight SDS -1.39 1.36 -4.5 2.4 140 -1.19 1.02 -3.2 1.0 51
Pretreatment
Δheight SDS during pretreat yr 0.07 0.17 -0.5 0.6 135 0.04 0.18 -0.6 0.4 48
GHmax of GH-profile 44.3 28.1 9.3 235.4 140 30.6 17.3 6.4 76.1 40
GHmax during AITT 37.6 22.4 3.0 124.9 113 36.7 21.9 7.6 98.1 51
At GH start
SEX (min = girls, max = boys) 32 108 140 18 33 51
Age (yrs) 8.66 2.34 3.3 12.9 140 7.88 2.05 3.4 11.9 51
Height SDS -2.86 0.61 -4.8 -1.7 140 -2.80 0.56 -4.2 -2.0 51
Weight SDS -2.61 1.02 -5.3 1.6 140 -2.46 1.11 -4.9 1.3 51
Father height SDS -1.04 1.08 -4.9 1.9 140 -0.71 0.91 -2.2 1.7 51
Mother height SDS -1.39 1.04 -3.8 1.2 140 -0.88 0.87 -2.6 1.0 51
Diff SDS -2.12 0.74 -4.6 -0.4 140 -2.37 0.77 -5.1 -0.8 51
IGF SDS -0.82 1.32 -5.1 3.0 140 -1.49 1.54 -5.3 1.4 51
Leptin (ng/mL) 3.51 2.71 1.1 27.8 140 3.70 3.30 1.7 21.8 51
During treatment
GH dose (IU/kg/day) 0.12 0.04 0.07 0.25 140 0.12 0.02 0.08 0.20 51
Change in height SDS 1st yr 0.68 0.21 0.2 1.4 140 0.77 0.23 0.4 1.6 51
Change in height SDS two yrs 1.06 0.32 0.2 1.9 104 1.21 0.33 0.7 2.1 34BMC Medical Informatics and Decision Making 2007, 7:40 http://www.biomedcentral.com/1472-6947/7/40
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New derived variables
In the set of possible predictor variables we have added
some derived variables, based on auxological measure-
ments, which were not included in our previous model
[1]. A well-known derived variable for the individual char-
acterization of growth is, for example, the height SDS. For
a child with normal growth, height SDS remains more or
less constant over time. In children with disturbed spon-
taneous growth, there will be a systematic increase or
decrease in SDS. By extending the height SDS with an
extra individual regression weight it was possible to
describe normal as well as disturbed spontaneous growth
[8]. This extra regression weight is computed by fitting the
observed pretreatment growth in SDS with a non-linear
'disturbed growth SDS' function. The intercept of this
function gives an indication of the level of normal growth
Table 2: Characteristics of children included born either SGA (a and b) or preterm (c and d). The data is presented for the Auxological 
model.
a. Model group b. Validation group
Variables Mean SD Min Max N Mean SD Min Max N
At birth
Gestational age (weeks) 39.4 1.3 37 42 144 39.2 1.5 37 42 34
Height SDS -2.58 0.93 -5.8 -0.5 144 -2.55 0.84 -5.4 -0.9 34
Weight SDS -2.25 0.89 -4.5 0.4 144 -2.19 0.80 -4.4 -0.6 34
Pretreatment
Δheight SDS during pretreat yr 0.02 0.19 -0.5 0.6 134 0.03 0.19 -0.3 0.7 32
GHmax of GH-profile 47.8 27.8 11.7 146.9 77 38.5 23.6 14.2 98.1 18
GHmax during AITT 34.6 26.2 3.0 160 133 24.3 17.8 5.9 76.1 28
At GH start
SEX (min = girls, max = boys) 34 110 144 14 20 34
Age (yrs) 8.1 2.51 3.1 13.3 144 7.8 2.20 3.2 11.4 34
Height SDS -3.04 0.65 -4.8 -1.5 144 -2.94 0.54 -4.2 -2.0 34
Weight SDS -2.79 1.05 -6.2 1.6 144 -2.71 0.98 -4.9 0.0 34
Father height SDS -1.07 1.17 -4.9 1.9 144 -0.93 1.00 -2.8 1.7 34
Mother height SDS -1.39 1.09 -3.6 1.2 144 -1.28 0.97 -3.1 1.0 34
Diff SDS -2.29 0.82 -4.6 -0.4 144 -2.27 0.83 -5.1 -0.8 34
IGF SDS -0.81 1.46 -7.4 3.0 87 -1.02 1.64 -4.0 2.7 25
Leptin (ng/mL) 3.65 3.24 1.2 27.8 92 3.12 1.05 1.7 5.3 25
During treatment
GH dose (IU/kg/day) 0.11 0.03 0.07 0.22 144 0.11 0.02 0.09 0.18 34
Change in height SDS 1st yr 0.7 0.28 0.1 2.0 144 0.64 0.19 0.1 1.0 34
Change in height SDS two yrs 1.1 0.41 0.2 3.0 108 1.03 0.32 0.4 1.9 26
c. Model group d. Validation group
At birth
Gestational age (weeks) 34.4 1.7 30 36 36 34.4 2.5 27 36 11
Height SDS -2.57 1.96 -8.1 0.7 36 -1.75 1.55 -4.0 1.4 11
Weight SDS -2.18 1.66 -6.1 0.7 36 -1.78 1.6 -3.5 1.8 11
Pretreatment
Δheight SDS during pretreat yr -0.05 0.22 -0.4 0.5 32 0.03 0.1 -0.1 0.2 11
GHmax of GH-profile 44.1 25.9 14.3 134 22 28.6 10.5 15.4 48.9 10
GHmax during AITT 28.6 15.1 8.5 70.4 33 38.3 17.4 8.8 63.8 10
At GH start
SEX (min = girls, max = boys) 7 29 36 5 6 11
Age (yrs) 7.89 2.91 2.8 14.6 36 6.69 1.32 4.8 9.0 11
Height SDS -2.84 0.59 -4.1 -1.5 36 -2.61 0.36 -3.2 -2.0 11
Weight SDS -3.01 0.89 -5.2 -0.7 36 -2.40 1.14 -5.2 -0.2 11
Father height SDS -1.16 0.88 -3.4 0.4 36 -0.40 1.21 -2.8 1.3 11
Mother height SDS -1.02 0.89 -3.2 1.2 36 -0.68 1.26 -3.4 1.6 11
Diff SDS -2.2 0.72 -3.5 -1.0 36 -2.36 0.52 -3.3 -1.3 11
IGF SDS -1.54 1.19 -5.4 0.2 26 -1.12 1.41 -3.3 0.7 11
Leptin (ng/mL) 3.25 1.16 2.1 7.1 21 3.96 1.73 2.5 8 9
During treatment
GH dose (IU/kg/day) 0.11 0.03 0.08 0.19 36 0.14 0.03 0.10 0.18 11
Change in height SDS 1st yr 0.68 0.25 0.4 1.2 36 0.71 0.16 0.5 1.0 11
Change in height SDS two yrs 1.1 0.39 0.6 2.2 28 1.18 0.16 0.9 1.4 8BMC Medical Informatics and Decision Making 2007, 7:40 http://www.biomedcentral.com/1472-6947/7/40
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and the slope gives a measure of the amplitude and direc-
tion of disturbed growth. In the earlier model (ref 1 in the
manuscript) the theoretical extrapolation of the
'untreated' growth curve in height SDS beyond the start of
GH treatment was computed with an exponential curve
fitted with two height measurement points: the first at one
year before start of treatment and the second at start of
treatment. This exponential curve gave an estimate of the
growth curve if the child was not treated, but the form of
the curve was a best guess and not based on data fitting
over several years. The "untreated end level SDS" can be
compared with the target height SDS or other auxological
data and result in relevant prediction variables for predict-
ing the response to GH.
GH dose in the models
In most biological systems, the response to dose is loga-
rithmic, as it is for GH [28]. However, a linear dose rela-
tionship has been reported [4,29] in the GH-dose range
normally used (17–100 μg/kg/day). We therefore con-
structed models with either linear or logarithmic dose
transformations. As the SDres were similar, we present only
the linear dose models.
Ethics
The GH treatment studies were approved by the Ethical
Committees of the Medical Faculties of the Universities of
Göteborg, Lund, Linköping, Uppsala and Umeå and of
the Karolinska Institute. Informed consent was obtained
from all children (if old enough) and their parents.
Results
A. Prediction models
The variables available for modelling and those selected
are indicated in Table 3. Either length SDS or weight SDS
at birth could be used in the models with the same result
in terms of SDres. As measurement of birth length is not
performed in some countries, the weight SDS was used in
the models. Five prediction models were developed. The
auxological model was constructed first. The different
endocrine variables were then added to produce the endo-
crine models. Results are calculated for the first 1, 2 and 3
years of GH treatment (Table 4). Results for the SGA and
preterm children are shown in Table 5. The daily dose of
GH/kg body weight was constant in time and included in
all the models with variable name DoseG. The equations
for the models are given in Additional file 1.
I. Auxological model
This model was created using growth data collected
between the first years of life and the start of treatment,
together with parental heights. The SDres for the first-year
response to GH treatment in the Model group was 0.23
SDS.
II. Endocrine models
1. IGF-I+leptin: In this model, IGF-I SDS and leptin levels
at the start of treatment were added to the auxological
model. The accuracy of the prediction was improved (i.e.
the SDres was reduced) giving an SDres for the Model group
of 0.19 SDS.
2. GHAITT+IGF-I+leptin: The peak value of the GHAITT and
IGF-I and leptin at the start of treatment were added to the
auxological model, giving a similar SDres as above (0.19
SDS). Thus, addition of GHAITT  did not improve the
model.
3. GH24 h: Information from the spontaneous GH profile
was obtained and the peak value (found to be most
informative) was selected, and used together with the aux-
ological model, giving an SDres of 0.16 SDS.
4. GH24 h+IGF-I+leptin: When IGF-I and leptin at the start
of treatment were added to the GH24 h model, the SDres
decreased to 0.15 SDS, indicating that this is the most
accurate model.
B. Validation of the models
The results from the validation indicated that the predic-
tion accuracy was consistent with the results from all the
Model groups, indicating that all the models are valid sta-
tistically (see Table 4, right column).
The observed growth in relation to the predicted growth
response is visualized for each child in the Validation
Birth size (weight SDS versus length SDS) of the study popu- lation Figure 1
Birth size (weight SDS versus length SDS) of the 
study population. Children in the model group are shown 
as open circles, children in the validation group as open trian-
gles and children born preterm as diamonds. Note the wide 
range of birth size and the continuous distribution.
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groups in Figure 2. Approximately 95% of the children
have an observed individual growth response within the 2
SDres for both models.
C. Children born SGA or preterm
Prediction and validation in short children born SGA were
within the expected range for all models (see Table 5). For
the group born preterm, predictions were within the
expected range with the least accurate auxology model.
For the endocrine models, a simple fine-tuning computed
on a preterm model group (n = 22) was needed to obtain
results with an SDres in the same range. The results of fine-
tuning the models are shown in Table 6.
Discussion
We here present growth prediction models to be used
when GH treatment is given to short prepubertal children
independent of GH status, gestational age or birth size.
This study presents validated prediction models with the
most accurate estimates of the growth response to GH
treatment available. The model with the best accuracy
using auxological and endocrine variables has a 2 SDres of
0.30 SDS, corresponding to a prediction interval of ± 1.2
cm in a 4-year-old boy. On the other hand, using only
auxological data, it is still possible to predict the individ-
ual growth response during the first year with a narrow
prediction interval of ± 1.9 cm in the same 4-year-old boy
(2 SDres of 0.46 SDS). This is possible due to non-linear
modelling and the inclusion of new mathematically
derived growth variables, based on clinical knowledge. In
the future, new prediction models adding data such as
bone markers [3], genetics or proteomic variables may
improve the accuracy of the models further, since the
information for computing the best model presented here
is not always available in clinical practice worldwide.
Therefore we think it is useful to search for the construc-
tion of simpler models with growth data more directly
related to the GH growth responsiveness. It will give more
insight in the underlying processes and can give better pre-
diction results when certain information like the parents
height or 24-hour GH profile is lacking.
As the models described here were developed in a group
of children with a wide range of values in the variables
used, these models tend to be more robust [6] than those
restricted by arbitrary cut-offs in, for example, birth size,
gestational age/preterm birth or GH secretion. Most other
published models have been developed from data from
children selected according to birth size [1-4] or GH status
[2-4]. In clinical practice this might be inconvenient, as
the models will not cover a large number of the children
who might be treated with GH. We also developed models
Table 3: Variables used in the different models.
Auxological model Endocrine models
IGF+leptin GHAITT+IGF+leptin GH24 h GH24 h+IGF+leptin
At birth
Gestational age (weeks) x x x x x
Length
Weight x x x x x
Gender x x x x x
Pretreatment growth
Height & weight
After 9 months x x x x x
At GH start
Age at start x x x x x
Height x x x x x
Weight x x x x x
Parental heights
Mother's height x x x x x
Father's height x x x x x
Biochemical
GHmax 24 h xx
GHmaxAITT x
IGF-I x x x
leptin x x x
GH dose xxx x xBMC Medical Informatics and Decision Making 2007, 7:40 http://www.biomedcentral.com/1472-6947/7/40
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based exclusively on data from children born SGA (data
not shown). These were as accurate (same SDres) as those
with a broader range in birth size.
The value of our multivariate algorithms is strengthened
by the use of one group of children to develop the models,
and use of a separate group of children for validation. The
algorithms, therefore, fulfil the criteria of prediction mod-
els [6]. The non-linear approach used in the models may
have contributed to the more narrow prediction interval
compared with models constructed by others using a lin-
ear approach [2-5]. Our simplest auxological model gives
a better prediction interval than previous models for GH-
deficient children and for short children born AGA, who
have various GH secretory capacities [1]. Also, we observe
a similar prediction interval for children born SGA, as in
models constructed only for children born SGA (± 2.2 cm
in a 6.6-year-old child) [4].
Compared with the KIGS prediction model for children
born SGA [4], we obtain a broader prediction range in
SDS and cm/year. This will provide a more appropriate
prediction of high responders. The risk of overfitting (i.e.
constructing too accurate predictions in a model group,
which are not reliable and therefore give bad validation
results) has been debated [30]. In our study, overfitting
was prevented, by selecting stepwise subsets of trans-
formed original variables that gave the best overall predic-
tion result. The prevention of overfitting is proven by the
consistent validation results of our models. The low SDres
for the different models is a sign of the low ratio of
extreme residuals, i.e. high predictive accuracy for most
individual children. The greater the accuracy in the model
the smaller the prediction error, and the lower the risk of
making a sub-optimal clinical decision about a treatment.
The models presented serve as a practical clinical tool for
selecting children for successful GH treatment.
In the prediction models we use indirect variables for fat
(weight and leptin), liver (IGF-I) and bone (linear
growth). The finding that the GHmax value from the spon-
taneous profile was the most informative variable, and
more predictive than the GH peak in the provocation test,
was known previously [1], and reflects both the higher
reproducibility of the former and its greater relevance to
growth [31,32]. The GH value obtained during the spon-
taneous profile and growth response to GH therapy
reflects the interplay between these two variables. We have
reported [10] that nighttime GHmax has nearly the same
predictive value for the growth response to GH treatment
Table 4: SDres results in the total Model group (left) and total Validation group (right) giving the first, second and third year response. 
SDstandRes gives the ratio SDres/SDresModelgroup, 2*cm 3 y gives the 2 SD prediction interval in cm at 3 years of age and 2*cm 7 y 
gives this interval at 7 years of age.
Model group Validation group
Models nS D res SDstandRes 2*cm 3 y 2*cm 7 y n SDres
1 yr response
A. Auxological model 415 0.231 1 1.7 2.4 112 0.230
B. Auxological+endocrine models
IGF+leptin 199 0.191 1 1.4 2.0 82 0.209
GHAITT+IGF+leptin 172 0.191 1 1.4 2.0 71 0.205
GH24 h 188 0.164 1 1.2 1.7 60 0.165
GH24 h+IGF+leptin 140 0.154 1 1.1 1.6 51 0.156
2 yrs response
A. Auxological model 305 0.340 1 2.5 3.5 77 0.351
B. Auxological+endocrine models
IGF+leptin 154 0.266 1 1.9 2.7 55 0.290
GHAITT+IGF+leptin 138 0.260 1 1.9 2.7 45 0.280
GH24 h 133 0.276 1 2.0 2.8 43 0.289
GH24 h+IGF+leptin 105 0.246 1 1.8 2.5 34 0.261
3 yrs response
A. Auxological model 191 0.432 1 3.2 4.5 27 0.470
B. Auxological+endocrine models
IGF+leptin 109 0.327 1 2.4 3.4 17 0.370
GHAITT+IGF+leptin 98 0.329 1 2.4 3.4 12 0.358
GH24 h 86 0.353 1 2.6 3.6 14 0.400
GH24 h+IGF+leptin 73 0.305 1 2.2 3.1 9 0.343BMC Medical Informatics and Decision Making 2007, 7:40 http://www.biomedcentral.com/1472-6947/7/40
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as the maximum level from 24 h GH sampling. The pro-
file GHmax was informative to the point that adding IGF-I
and leptin data to the 24 h model improved the predic-
tion interval only slightly. These variables, however,
improved the prediction interval if added to the auxolog-
ical model. The effect of GH on fat tissue seems to be
closely related to the growth response to GH treatment
[12,33]. Leptin can be used as an indirect marker of
responsiveness, in fat tissue either mirroring nutritional
status or as a sign of GHD.
In clinical practice, if it is not possible to perform a spon-
taneous GH profile, IGF-I and leptin are informative,
although not as useful as adding the GHmax from the pro-
file. To make a more informed selection of those children
who will benefit from GH treatment, a decision can be
made among the more simple auxological model, keeping
in mind the sub-optimal SDres, or the more precise endo-
crine models with GHmax or IGF-I and leptin. Although
the latter models are more costly in terms of the investiga-
tions required, they are improved for selecting children
for treatment.
Authorities in Europe and the USA have approved GH
treatment for short children born SGA, regardless of their
GH secretory status. Various treatment regimens have
been studied with high-dose GH treatment, based on the
observation of elevated circulating GH concentrations in
SGA newborns [34,35]. A correlation has been observed
between the GH dose and the early growth response [4].
Some of these children, however, have satisfactory catch-
up growth with a dose of 33 μg/kg/day, especially those
who start treatment at a young age [9,35,36]. These chil-
dren have been observed to have significant variability in
their growth response to treatment with fixed doses of
GH. In this group, therefore, GH dosing should be indi-
vidualized using prediction models that give an estimate
of responsiveness.
Conclusion
The models presented here are independent of birth size
and provide the highest prediction accuracy available.
They serve as a tool to identify those children who may
benefit from GH treatment, and to help choose the opti-
mal GH dose during the first years of treatment in order to
optimize the individual catch-up growth response.
Abbreviations
AGA appropriate for gestational age
AITT arginine-insulin tolerance test
Table 5: SDres results for children born SGA, giving the first, second and third year response. Model group (left) and total Validation 
group (right). SDstandRes gives the ratio SDres/SDresModelgroup, 2*cm 3 y gives the 2 SD prediction interval in cm at 3 years of age 
and 2*cm 7 y gives this interval at 7 years of age.
Model group Validation group
Models nS D res SDstand Res 2*cm 3 y 2*cm 7 y n SDres
1 yr response
A. Auxological model 144 0.221 0.96 1.6 2.3 34 0.211
B. Auxological+endocrine models
IGF+leptin 83 0.188 0.98 1.4 1.9 25 0.177
GHAITT+IGF+leptin 72 0.186 0.97 1.4 1.9 20 0.185
GH24 h 77 0.169 1.03 1.2 1.7 18 0.137
GH24 h+IGF+leptin 68 0.167 1.08 1.2 1.7 17 0.107
2 yrs response
A. Auxological model 112 0.326 0.96 2.4 3.4 27 0.343
B. Auxological+endocrine models
IGF+leptin 69 0.284 1.07 2.1 2.9 21 0.295
GHAITT+IGF+leptin 61 0.268 1.03 2.0 2.8 16 0.270
GH24 h 60 0.292 1.06 2.1 3.0 15 0.297
GH24 h+IGF+leptin 55 0.266 1.08 1.9 2.7 13 0.280
3 yrs response
A. Auxological model 77 0.440 1.02 3.2 4.5 9 0.459
B. Auxological+endocrine models
IGF+leptin 49 0.338 1.03 2.5 3.5 7 0.361
GHAITT+IGF+leptin 43 0.321 0.98 2.3 3.3 4 0.326
GH24 h 42 0.388 1.10 2.8 4 6 0.380
GH24 h+IGF+leptin 39 0.336 1.10 2.5 3.5 5 0.361BMC Medical Informatics and Decision Making 2007, 7:40 http://www.biomedcentral.com/1472-6947/7/40
Page 10 of 12
(page number not for citation purposes)
Table 6: SDres results for children born preterm, giving the first and second year response. Model group (left) and total Validation 
group (right). SDstandRes gives the ratio SDres/SDresModelgroup, 2*cm 3 y gives the 2 SD prediction interval in cm at 3 years of age 
and 2*cm 7 y gives this interval at 7 years of age.
Model group Validation group
Models NS D res SDstandRes 2*cm 3 y 2*cm 7 y n SDres
1 yr response
A. Auxological model 36 0.185 0.80 1.4 1.9 11 0.147
B. Auxological+endocrine models
IGF+leptin 21 0.159 0.83 1.2 1.6 9 0.124
GHAITT+IGF+leptin 18 0.161 0.84 1.2 1.7 8 0.117
GH24 h 22 0.124 0.75 0.9 1.3 10 0.128
GH24 h+IGF+leptin 16 0.125 0.81 0.9 1.3 8 0.120
2 yr response
A. Auxological model 28 0.273 0.80 2.0 2.8 8 0.179
B. Auxological+endocrine models
IGF+leptin 19 0.228 0.86 1.7 2.4 7 0.094
GHAITT+IGF+leptin 16 0.263 1.01 1.9 2.7 6 0.087
GH24 h 16 0.176 0.64 1.3 1.8 7 0.158
GH24 h+IGF+leptin 14 0.164 0.67 1.2 1.7 6 0.102
The SD of the residuals (SDres) in relation to the predicted growth response in the validation group Figure 2
The SD of the residuals (SDres) in relation to the predicted growth response in the validation group. Individual 
circles show each child. The 2 SD interval for the model group is indicated by broken lines. Note that 2 SD of the validation 
group for both models are within the confidence interval, despite the more narrow SDres.
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Diff SDS the intra-family difference in SDS (i.e. the differ-
ence in height SDS of the child compared to his/her MPH
SDS)
GHAITT the estimated maximal GH level from AITT
GHD GH deficient
GHmax the estimated maximal GH level from the sponta-
neous GH profile
IGF-I insulin-like growth factor-I
IGF-II insulin-like growth factor-II
IGFBP-3 IGF binding protein 3
MPH mid-parental height SDS
SDS SD score
SDres root mean square error of the residuals
SGA small for gestational age
GH24 h maximal GH level during a 24 h profile
GHAITT peak GH at AITT
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